Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Blood and Lymphatic Cancer: Targets and Therapy · 2018
DOI: 10.2147/blctt.s169529 ↗Kurz gefasst
Korrektur in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2018. Verfasst von Theodora Anagnostou und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Anagnostou, T., & Litzow, M. (2018). Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]. Blood and Lymphatic Cancer: Targets and Therapy. https://doi.org/10.2147/blctt.s169529
Vancouver
Anagnostou T, Litzow M. Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]. Blood and Lymphatic Cancer: Targets and Therapy. 2018. doi:10.2147/blctt.s169529
BibTeX
@article{Anagnostou2018,
author = {Anagnostou, Theodora and Litzow, Mark},
title = {Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]},
journal = {Blood and Lymphatic Cancer: Targets and Therapy},
year = {2018},
doi = {10.2147/blctt.s169529}
}
EUVIMED